Table 3

Hematologic response to therapy

Phase 1Phase 2Total
Evaluable patients* 14 10 24 
CR 4 4 8 
VGPR 0 1 1 
PR 2 1 3 
Response ≥ VGPR 4 5 9 (37.5%) 
Phase 1Phase 2Total
Evaluable patients* 14 10 24 
CR 4 4 8 
VGPR 0 1 1 
PR 2 1 3 
Response ≥ VGPR 4 5 9 (37.5%) 

PR, partial response; VGPR, very good partial response.

*

Evaluable patients: completing 3 cycles of treatment.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal